Académique Documents
Professionnel Documents
Culture Documents
181
Chapter 23
Staging is based on American Joint Committee on Cancer Staging, Fifth Edition (10).
Results
All Bladder Cancers
Distribution and survival by age, sex, and race
Of the 67,528 adult bladder cancers, 79.3% were diagnosed at 60 years of age or older (Table 23.2). The greatest frequency occurred in the 70-79 age group, and 59.4% were between the ages of 60-79 years. Most were male and the overwhelming majority (> 90%) were white. Overall, males had greater relative survival rates compared with females, while whites had greater relative survival rates than blacks. White males had the greatest 5-year relative survival rate (85%), followed in order by white females (77%), black males (69%), and black females (55%). The median survival times were 103 months for white males and 102 for white females compared with 67 months for black males and 40 months for black females (Table 23.3, Figure 23.1). White males and females diagnosed between the ages of 20 and 49 years had the greatest observed and relative survival percentages compared with blacks (Table 23.3). The median survival time was greater than 10 years for white males and females and black males and females. For persons over age 50, white males had the greatest observed and relative 5-year survival rate, while black females had the lowest. As anticipated, differences between observed and relative survival percentages were greatest in the 50+ age group.
Figure 23.1: Cancer of the Urinary Bladder: Relative Survival Rates (%) by Race and Sex, Ages 20+, 12 SEER Areas, 19882001
Months after diagnosis White Male White Female Black Male Black Female
Table 23.1: Cancer of the Urinary Bladder: Number of Cases and Exclusions by Reason, 12 SEER Areas, 1988-2001 Number Number Selected/Remaining Reason for Exclusion/Selection Excluded 86,187 69,302 68,934 68,475 68,409 68,344 67,746 67,581 67,528 0 16,885 368 459 66 65 598 165 53 Select 1988-2001 diagnosis (Los Angeles for 1992-2001 only) Select first primary only Exclude death certificate only or at autopsy Exclude unknown race Exclude alive with no survival time Exclude children (Ages 0-19) Exclude no or unknown microscopic confirmation Exclude sarcomas Exclude carcinoids
182
Chapter 23
Table 23.2: Cancer of the Urinary Bladder: Number and Distribution of Cases by Age (20+), Race, and Sex, 12 SEER Areas, 1988-2001 Race/Sex White Total Age Group (Years) Total 20-39 40-49 50-59 60-69 70-79 80+ Cases 67,528 1,318 3,661 9,059 17,864 22,198 13,428 Percent 100.0 2.0 5.4 13.4 26.5 32.9 19.9 Cases 46,342 846 2,550 6,388 12,840 15,466 8,252 Male Percent 100.0 1.8 5.5 13.8 27.7 33.4 17.8 Female Cases 15,296 322 723 1,840 3,519 4,853 4,039 Percent 100.0 2.1 4.7 12.0 23.0 31.7 26.4 Cases 1,960 60 179 352 530 560 279 Male Percent 100.0 3.1 9.1 18.0 27.0 28.6 14.2 Black Female Cases 1,085 21 52 118 255 357 282 Percent 100.0 1.9 4.8 10.9 23.5 32.9 26.0
Table 23.3: Cancer of the Urinary Bladder: Number of Cases, Median Survival Time (Months) and 5-Year Survival Rates (%) by Race, Sex, and Age Group, Ages 20+, 12 SEER Areas, 1988-2001 Median 5-Year Survival Survival Rate (%) Race, Sex, and Age Time Group (Years) Cases (Months) Obs Exp Rel White Females, 20-49 White Males, 20-49 Black Females, 20-49 Black Males, 20-49 White Females, 50+ White Males, 50+ Black Females, 50+ Black Males, 50+ White Females, 20+ White Males, 20+ Black Females, 20+ Black Males, 20+ 1,045 3,396 73 239 14,251 42,946 1,012 1,721 15,296 46,342 1,085 1,960 > 120 > 120 > 120 > 120 93.0 94.8 36.9 58.0 101.7 102.8 39.5 66.7 88.9 89.4 58.5 72.9 60.3 63.1 42.1 49.5 62.2 65.1 43.2 52.4 99.0 97.9 97.7 95.1 79.1 75.0 76.5 72.6 80.4 76.7 77.9 75.3 89.8 91.2 59.7 76.6 76.2 84.2 55.0 68.0 77.3 84.8 55.4 69.3
Table 23.4: Cancer of the Urinary Bladder: Number and Distribution of Cases by Histology, Ages 20+, 12 SEER Areas, 1988-2001 ICD-O-3 Histology Cases Pct Total Papillary transitional cell carcinoma Papillary carcinoma, NOS (8050) Papillary trans. cell carcinoma ( 8130) Other Pap. Trans. (8121,8131) Nonpapillary transitional cell carcinoma Transitional cell carcinoma, NOS (8120) Trans. cell carcinoma, spindle cell ( 8122) Squamous cell carcinoma Squamous cell carcinoma, NOS (8070) Sq. cell carcinoma, keratinizing, NOS (8071) Other Sq. Cell (8051-8052,8072,8074,8076) Adenocarcinoma Adenocarcinoma, NOS ( 8140) Mucinous adenocarcinoma (8480) Mucin-producing adenocarcinoma (8481) Signet ring cell carcinoma (8490) Other Adeno (8141,8144,8255,8260,8310, 8320,8323,8440,8470,8472,8570) Small cell carcinoma and related neuroendocrine tumors (8041-8042) Other Neoplasm, malignant (8000) Carcinoma, NOS (8010) Carcinoma, undifferentiated type, NOS (8020) Other (8001-8002,8004,8012,8021-8022, 8030,8032-8033,8044,8046,8082-8083, 8230,8262,8560,8700,8720,8933,8935,8940, 8950-8951,9064,9100,9364) 67,528 100.0 47,399 610 46,779 10 17,211 17,167 44 918 697 193 28 838 480 89 80 94 95 158 1,004 112 705 39 70.2 0.9 69.3 0.0 25.5 25.4 0.1 1.4 1.0 0.3 0.0 1.2 0.7 0.1 0.1 0.1 0.1 0.2 1.5 0.2 1.0 0.1
148
0.2
183
Chapter 23
Table 23.5: Cancer of the Urinary Bladder: Number and Distribution of Cases, Median Survival Time (Months) and 5-Year Survival Rates (%) by Histology, Ages 20+, 12 SEER Areas, 1988-2001 Median 5-Year Survival Rate (%) Survival Time Histology Cases Percent (Months) Observed Expected Relative Total Papillary transitional cell carcinoma Nonpapillary transitional cell carcinoma Squamous cell carcinoma Adenocarcinoma Small cell carcinoma and related neuroendocrine tumors 67,528 47,399 17,211 918 838 158 100.0 70.2 25.5 1.4 1.2 0.2 101.1 > 120 50.3 9.5 31.3 13.3 63.7 71.8 46.6 23.7 34.5 21.8 77.8 78.5 76.1 76.7 79.7 77.9 81.9 91.5 61.2 30.9 43.3 26.2
Table 23.6: Cancer of the Urinary Bladder: Number and Distribution of Cases, Median Survival Time (Months) and 5-Year Survival Rates (%) by AJCC Stage (5th Edition), 12 SEER Areas, 1988-2001 AJCC Stage (5th Edition) Total Stage 0 Stage I Stage II Stage III Stage IV Unknown 5-Year Relative Median Survival Rate Survival (%) Time Percent (Months) Obs Exp Rel 100.0 43.9 12.8 6.7 3.7 5.6 27.3 101.1 > 120 108.3 54.6 28.3 9.7 80.6 63.7 77.8 78.0 79.3 68.1 77.7 47.7 76.2 35.8 78.7 11.8 79.9 57.4 75.3 81.9 98.4 87.7 62.6 45.5 14.8 76.3
Five-year observed and relative survival rates and median survival time were greatest for papillary transitional cell carcinoma compared with other histologic types (Table 23.5). Squamous cell carcinoma had the lowest median survival time, of 9.5 months.
Survival by stage
Observed and relative 5-year survival rates decreased through the progression of urinary bladder cancer to later stages (Table 23.6). Median survival times were greater than 10 years for stage 0 but less than 5 years for all other stages except stage I. Patients with unknown stage of disease had observed and relative 5-year survival rates and a median survival time that was higher than all other stages, except stages 0 and I. This finding suggests that a substantial proportion of patients with unknown stage had in situ (stage 0) or superficially invasive (stage I) disease.
Figure 23.2: Transitional Cell Carcinoma of the Urinary Bladder: Relative Survival Rates (%) by Histology, Race and Sex, Ages 20+, 12 SEER Areas, 1988-2001
100 90
Papillary White Male Papillary p y White Female Papillary Black Male Papillary Black Female Nonpapillary White Male Nonpapillary White Female Nonpapillary Black Male Nonpapillary Black Female
184
Chapter 23
Table 23.7: Transitional Cell Carcinoma of the Urinary Bladder: Number and Distribution of Cases by Histology, Age (20+), Race and Sex, 12 SEER Areas, 1988-2001 Race/Sex Age Group (Years) Total 20-39 40-49 Papillary 50-59 60-69 70-79 80+ Total 20-39 40-49 Nonpapillary 50-59 60-69 70-79 80+ White Total Cases 47,399 1,071 2,754 6,648 12,708 15,466 8,752 17,211 177 715 2,055 4,456 5,851 3,957 Percent 100.0 2.3 5.8 14.0 26.8 32.6 18.5 100.0 1.0 4.2 11.9 25.9 34.0 23.0 Male Cases 33,465 711 2,001 4,753 9,355 11,043 5,602 11,320 100 460 1,434 3,086 3,929 2,311 Percent 100.0 2.1 6.0 14.2 28.0 33.0 16.7 100.0 0.9 4.1 12.7 27.3 34.7 20.4 Female Cases 10,427 262 533 1,363 2,461 3,285 2,523 3,940 45 134 389 863 1,291 1,218 Percent 100.0 2.5 5.1 13.1 23.6 31.5 24.2 100.0 1.1 3.4 9.9 21.9 32.8 30.9 Male Cases 1,188 39 103 217 321 347 161 604 13 52 102 166 173 98 Percent 100.0 3.3 8.7 18.3 27.0 29.2 13.6 100.0 2.2 8.6 16.9 27.5 28.6 16.2 Black Female Cases 527 11 19 65 122 178 132 423 6 23 36 95 153 110 Percent 100.0 2.1 3.6 12.3 23.1 33.8 25.0 100.0 1.4 5.4 8.5 22.5 36.2 26.0
Histology
For papillary transitional cell carcinoma, relative survival rates for both males and females were higher for white than black adults (Figure 23.2). Between the ages of 20 and 49 years, white males and females had the highest five-year relative survival rates (Table 23.8). In this age range, median survival times were greater than 10 years for males and females and both races. For persons 50 and older, white males had the highest 5-year relative survival rate of 92%, while black females had the lowest percentage (76%). The median survival times were higher for whites than blacks in both sexes. For nonpapillary transitional cell carcinoma, relative survival rates were highest for white males, followed by white females and black males with black females having the lowest rates (Figure 23.2). Between the ages of 20 and 49 years, whites had the highest five-year relative survival rates (Table 23.8). Black females in this age group had a very low median survival time of 33 months, but this should be interpreted with caution since there were only 29 cases. For persons 50 and older, white males had the highest 5-year relative survival rate of 65%, while black females had the lowest rate (38%). For ages 20+, the median survival times were higher for whites than blacks in both sexes and were three times as long in white males than black females. Survival rates in adults were substantially higher in both races and sexes for papillary transitional cell carcinoma
compared with nonpapillary transitional cell carcinoma. This was especially true for the 50+ age group.
185
Chapter 23
Table 23.8: Transitional Cell Carcinoma of the Urinary Bladder: Number of Cases, Median Survival Time (Months) and 5-Year Survival Rates (%) by Histology, Race, Sex, and Age (20+), 12 SEER Areas, 1988-2001 Median Survival Time (Months) > 120 > 120 > 120 > 120 > 120 > 120 111.7 85.2 87.0 > 120 > 120 88.6 102.4 50.3 > 120 > 120 32.9 > 120 32.6 54.3 17.8 27.0 34.7 57.2 19.0 29.2
5-Year Survival Rate (%) Observed 71.8 97.0 94.7 88.7 85.7 71.2 69.7 58.5 61.0 73.2 71.7 60.2 63.9 46.6 69.7 72.5 43.3 55.9 39.8 47.9 29.1 34.6 41.1 49.1 30.1 37.0 Expected 78.5 99.0 98.0 97.9 95.1 80.0 75.5 77.1 72.9 81.5 77.3 78.3 75.6 76.1 98.9 97.8 97.5 95.0 77.2 73.8 76.2 71.7 78.2 75.0 77.6 74.2 Relative 91.5 98.0 96.7 90.2 89.4 89.0 92.3 75.5 83.4 89.8 92.7 76.6 84.2 61.2 70.4 74.1 44.2 58.5 51.5 64.9 38.2 47.7 52.6 65.4 38.7 49.3
Histology
Race, Sex, and Age Group (Years) All White Females, 20-49 White Males, 20-49 Black Females, 20-49 Black Males, 20-49 White Females, 50+
Cases 47,399 795 2,712 30 142 9,632 30,753 497 1,046 10,427 33,465 527 1,188 17,211 179 560 29 65 3,761 10,760 394 539 3,940 11,320 423 604
Papillary
White Males, 50+ Black Females, 50+ Black Males, 50+ White Females, 20+ White Males, 20+ Black Females, 20+ Black Males, 20+ All White Females, 20-49 White Males, 20-49 Black Females, 20-49 Black Males, 20-49 White Females, 50+
Nonpapillary
White Males, 50+ Black Females, 50+ Black Males, 50+ White Females, 20+ White Males, 20+ Black Females, 20+ Black Males, 20+
Table 23.9: Papillary Transitional Cell Carcinoma of the Urinary Bladder: Number and Distribution of Cases and Median Survival Time (Months) by AJCC Stage (5th Edition), Race, and Sex, Ages 20+, 12 SEER Areas, 1988-2001 Race/Sex White Male Median Survival Time Percent (Months) 100.0 55.7 13.9 3.5 1.5 1.5 23.9 > 120 > 120 112.8 65.2 34.5 14.0 105.1 Female Median Survival Time Percent (Months) 100.0 57.5 12.7 3.6 0.9 2.1 23.2 > 120 > 120 110.4 58.9 22.3 10.6 114.1 Male Median Survival Time (Months) 102.4 > 120 90.3 67.6 14.8 14.0 81.5 Black Female Median Survival Time (Months) 88.6 > 120 94.6 33.3 ~ 9.2 78.5
AJCC Stage (5th Edition) Total Stage 0 Stage I Stage II Stage III Stage IV Unknown
~
Cases Percent 1,188 551 186 60 36 28 327 100.0 46.4 15.7 5.1 3.0 2.4 27.5
Cases Percent 527 233 79 40 10 27 138 100.0 44.2 15.0 7.6 1.9 5.1 26.2
186
Chapter 23
as unstaged. Among those with known stage, the greatest number was stage IV for white females, black males, and black females and stage 0 for white males (Table 23.10). Stage I accounted for approximately 10% of all cancers in each race and sex group (Table 23.10). The percentage of stage IV nonpapillary transitional cell carcinomas was highest among black females (21.7%) compared with black males (16.7%), white females (16.3%) or white males (11.5%). Median survival times were higher among males compared with females in each race group, except for stage 0 in whites where they were both >10 years and stage IV for blacks (Table 23.10). Relative survival curves for nonpapillary transitional cell carcinoma by stage and sex were also higher for whites
Figure 23.3: Male Papillary Transitional Cell Carcinoma of the Urinary Bladder: Relative Survival Rates (%) by AJCC Stage (5th Edition) and Race, Ages 20+, 12 SEER Areas, 1988-2001
100 90
Relat tive Survi ival Rate (%)
80 70 60 50 40 30 20 10 0 0 12 24 36 48 60 72 84 96 108 120 Months after diagnosis White, , Stage g 0 White, Stage I White, Stage II White, Stage III White Stage IV White, Black, Stage 0 Black, Stage I Black, , Stage g II Black, Stage III Black, Stage IV
80 70 60 50 40 30 20 10 0 0 12 24 36 48 60 72 84 96 108 120 Months after diagnosis White, Stage 0 White, Stage I White, Stage II White, Stage III Whi S White, Stage IV Black, Stage 0 Black, Stage I Black Stage II Black, Black, Stage IV
Table 23.10: Nonpapillary Transitional Cell Carcinoma of the Urinary Bladder: Number and Distribution of Cases and Median Survival Time (Months) by AJCC Stage (5th edition), Race, and Sex, Ages 20+, 12 SEER Areas, 1988-2001 Race/Sex White Male AJCC Stage (5th Edition) Total Stage 0 Stage I Stage II Stage III Stage IV Unknown Median Survival Time (Months) 57.2 > 120 93.1 53.3 28.2 10.6 54.1 Female Median Survival Time Cases Percent (Months) Cases 3,940 540 385 620 319 642 1,434 100.0 13.7 9.8 15.7 8.1 16.3 36.4 34.7 > 120 85.6 40.0 23.4 8.6 28.5 604 74 54 80 53 101 242 Male Median Survival Time (Months) 29.2 > 120 96.9 32.8 18.9 7.4 35.6 Black Female Median Survival Time (Months) 19.0 76.3 57.0 23.5 11.1 8.0 20.1
187
Chapter 23
rates were higher for papillary carcinomas than nonpapillary at each stage and grade (Table 23.11). In general for each histologic subtype within each stage, survival decreased as tumor grade increased except grade IV where survival was similar to grade III and sometimes slightly higher by stage. When early stage transitional cell carcinomas were separated into papillary and nonpapillary histologic subtypes by tumor grade, 5-year relative survival rates were lower among the high-grade nonpapillary carcinomas for each race and sex group (Table 23.12). Although these highgrade nonpapillary carcinomas comprised a small proportion of very early transitional cell carcinomas in whites, they comprised a higher percentage for black males and black females which contributed to the lower survival rates
Figure 23.5: Male Nonpapillary Transitional Cell Carcinoma of the Urinary Bladder: Relative Survival Rates (%) by AJCC Stage (5th Edition) and Race, Ages 20+, 12 SEER Areas, 19882001
100 90
Re elative Sur rvival Rat te (%)
Survival by stage
White, Stage 0 Whit St White, Stage I White, Stage II White, Stage III White Stage IV White, Black, Stage 0 Black, Stage I Black, Stage II Black, Stage III Black, Stage IV
The stage distribution for squamous cell carcinoma was similar for males and females (Table 23.14). For stage 0/I disease, males had a much higher median survival time than females. For females, stage 0/I had low median survival time but it was based on a small number of cases. Overall, median survival times were relatively low for squamous cell stages II-IV compared with other histologies.
Figure 23.6: Female Nonpapillary Transitional Cell Carcinoma of the Urinary Bladder: Relative Survival Rates (%) by AJCC Stage (5th Edition) and Race, Ages 20+, 12 SEER Areas, 19882001
100 90
Figure 23.7: Early Stage Transitional Cell Carcinoma of the Urinary Bladder: Relative Survival Rates (%) by AJCC Stage 0 and I, Histology, and Grade, Ages 20+, 12 SEER Areas, 19882001
100
Rela ative Surv vival Rate e (%)
90 80 70 60 50 40 30 20 10
Stage 0 Papillary, Grade I & II Stage 0 Papillary, Grade III & IV Stage I Papillary, Papillary Grade I & II Stage I Papillary, Grade III & IV Stage 0 Nonpapillary, Grade I & II Stage 0 Nonpapillary, Grade III & IV Stage I Nonpapillary, Grade I & II Stage I Nonpapillary, Grade III & IV 0 12 24 36 48 60 72 84 96 108 120 Months after diagnosis
80 70 60 50 40 30 20 10 0 0 12 24 36 48 60 72 84 96 108 120 Months after diagnosis White, , Stage g 0 White, Stage I White, Stage II White, Stage III White Stage IV White, Black, Stage 0 Black, Stage I Black, Stage II Black, Stage S III Black, Stage IV
188
Chapter 23
Table 23.11: Transitional Cell Carcinoma of the Urinary Bladder: Number of Cases and 5-Year Relative Survival Rates (RSR) (%) of White and Blacks by Histology, AJCC Stage (5th Edition) and Tumor Grade, Ages 20+, 12 SEER Areas, 1988-2001 Tumor Grade Total AJCC Stage (5th Edition) Cases Total Stage 0 Stage I Papillary Stage II Stage III Stage IV Unknown Total Stage 0 Stage I Nonpapillary Stage II Stage III Stage IV Unknown
~
II 5-Yr RSR (%) 98.7 92.2 72.1 57.6 24.0 92.7 83.4 94.5 87.4 68.0 45.4 16.3 83.3
III 5-Yr RSR (%) 79.0 95.9 84.7 63.2 43.1 19.6 76.0 49.6 92.3 74.8 59.7 40.9 12.7 51.9
IV 5-Yr RSR (%) 71.6 91.5 84.0 67.5 49.2 22.8 70.2 48.0 90.6 75.8 61.7 50.1 16.4 45.4
Unknown 5-Yr RSR (%) 93.5 98.7 94.9 61.0 ~ ~ 85.9 74.8 90.1 82.6 68.0 35.2 7.3 67.9
Histology
5-Yr RSR (%) 91.6 99.1 90.0 66.5 49.1 21.1 86.9 60.9 93.9 80.9 61.1 43.8 13.7 60.8
Cases
Cases 3,249 2,101 916 348 452 3,263 7,245 344 766 1,404 840 1,218 2,673
Cases 2,437 535 464 357 149 193 739 3,367 131 295 744 433 698 1,066
Cases 1,878 1,089 183 29 12 18 547 2,116 965 112 52 39 126 822
45,607 25,409 6,242 1,645 641 792 10,878 16,287 2,786 1,787 2,372 1,397 2,138 5,807
99.3 21,410 100.0 13,500 96.2 81.2 ~ ~ 95.2 95.1 97.5 91.9 ~ ~ ~ 92.2 2,737 318 122 116 4,617 2,589 820 485 161 78 89 956
95.5 10,329
Table 23.12: Stage 0 & I Transitional Cell Carcinoma of the Urinary Bladder (with Known Grade): Number of Cases and 5-Year Relative Survival Rates (%) by Race, Sex, Histology, and Grade, Ages 20+, 12 SEER Areas, 1988-2001 Histology Papillary Grade Low-Grade (I & II) Cases Race/Sex Total (White & Black) White Male White Female Black Male Black Female 24,030 17,472 5,774 555 229 5-Year Relative Survival Rate (%) 98.6 99.5 96.9 92.8 92.4 High-Grade (III & IV) Cases 6,349 4,870 1,256 155 68 5-Year Relative Survival Rate (%) 91.1 93.3 83.7 88.8 74.8 Low-Grade (I & II) Cases 1,960 1,452 440 43 25 5-Year Relative Survival Rate (%) 93.9 94.2 92.9 87.5 72.8 Nonpapillary Grade High-Grade (III & IV) Cases 1,536 1,153 300 47 36 5-Year Relative Survival Rate (%) 81.2 83.7 74.3 76.4 56.9
Table 23.13: Squamous Cell Carcinoma of the Urinary Bladder: Number and Distribution of Cases by Age (20+), Race, and Sex, 12 SEER Areas, 1988-2001 Race/Sex White Total Age Group (Years) Total 20-59 60-69 70-79 80+ Cases 918 176 220 278 244 Percent 100.0 19.2 24.0 30.3 26.6 Male Cases 398 83 92 127 96 Percent 100.0 20.9 23.1 31.9 24.1 Female Cases 377 55 85 116 121 Percent 100.0 14.6 22.5 30.8 32.1 Male Cases 56 17 14 16 9 Percent 100.0 30.4 25.0 28.6 16.1 Black Female Cases 55 11 19 10 15 Percent 100.0 20.0 34.5 18.2 27.3
189
Chapter 23
Survival curves for males were higher than females for stages 0/I and II squamous cell carcinoma (Figure 23.9). In contrast, for stages III and IV, females had higher survival for most years.
Adenocarcinoma
Survival by age, sex, and race
Overall, less than 30% of all cases were diagnosed when younger than 60 years (Table 23.15). Black males and females had a younger age distribution than white males and females. The male to female ratio for whites was 1.9 and for blacks was 1.5. Overall, males had a slightly higher 5-year relative survival rate (48%) compared with females (36%) diagnosed with adenocarcinoma (Figure 23.10).
Survival by stage
Later stage (III and IV) adenocarcinoma was more frequent in females compared with males (Table 23.16), which contributed to an all stage median survival time that was higher in males compared with females. The survival curves, however, were not consistently higher for males compared to females within stage (Figure 23.11).
Discussion
For the 67,528 cases presented herein, the greatest number of bladder cancers was diagnosed between the ages of 60 and 79 years of age. Among adults, the 5-year relative survival rate was greatest for white males (85%) followed by white females (77%), black males (69%), and black females (55%). Transitional cell carcinoma was the most common histologic type, accounting for over 95% of all bladder cancers. Within this type, papillary transitional cell carcinoma was the most common subtype, accounting for 70.2% of all bladder cancers and nonpapillary transitional cell carcinoma accounting for an additional 25.5% of the bladder cases. The next most frequent histologic type was squamous cell carcinoma, which comprised 1.4% of all urinary bladder cancers, followed by adenocarcinoma, which accounted for 1.2%. Papillary transitional cell carcinoma had the highest median survival time (> 10 years) followed by nonpapillary transitional cell carcinoma, adenocarcinoma, and squamous cell carcinoma. The male to female ratio was greatest for transitional cell carcinoma and least for squamous cell carcinoma. For papillary transitional cell carcinoma, most were diagnosed at stages 0 and I. When early stage transitional cell carcinomas were stratified by histologic subtype and tumor grade, high-grade nonpapillary lesions had the poorest survival.
Table 23.14: Squamous Cell Carcinoma of the Urinary Bladder: Number and Distribution of Cases and Median Survival Time (Months) by AJCC Stage (5th Edition) and Sex, Ages 20+, 12 SEER Areas, 1988-2001 Male Female AJCC Stage (5th Edition) Total Stage 0/I Stage II Stage III Stage IV Unknown Median Survival Time (Months) Cases 10.0 > 120 46.4 16.9 4.8 7.3 35 72 73 129 139 Median Survival Time (Months) 9.1 24.4 30.4 23.6 5.3 6.6
470 100.0
448 100.0
190
Chapter 23
Figure 23.8: Squamous Cell Carcinoma of the Urinary Bladder: Relative Survival Rates (%) by Sex, Ages 20+, 12 SEER Areas, 1988-2001
100 90
Relative Su urvival Ra ate (%)
80 70 60 50 40 30 20 10 0 0 12 24 36 48 60 72 84 96 108 120 Months after diagnosis Male Stage 0/I Male Stage II Male Stage III Male Stage IV Female Stage 0/I Female Stage II Female Stage III Female Stage IV
Figure 23.10: Adenocarcinoma of the Urinary Bladder: Relative Survival Rates (%) by Sex, Ages 20+, 12 SEER Areas, 1988-2001
Figure 23.11: Adenocarcinoma of the Urinary Bladder: Relative Survival Rates (%) by Sex and AJCC Stage (5th Edition), 12 SEER Areas, 1988-2001
100 90
Rela ative Surv vival Rate (%)
100 90
Rela ative Surv vival Rate e (%)
Male Stage 0/I Male Stage II Male Stage III Male Stage IV Female Stage 0/I Female Stage S II Female Stage III Female Stage IV
Table 23.15: Adenocarcinoma of the Urinary Bladder: Number and Distribution of Cases by Age (20+), Race, and Sex, 12 SEER Areas, 1988-2001 Race/Sex White Total Age Group (Years) Total 20-59 60-69 70+ Cases 838 244 203 391 Percent 100.0 29.1 24.2 46.7 Cases 454 120 122 212 Male Percent 100.0 26.4 26.9 46.7 Female Cases 242 61 47 134 Percent 100.0 25.2 19.4 55.4 Cases 60 29 16 15 Male Percent 100.0 48.3 26.7 25.0 Black Female Cases 41 15 10 16 Percent 100.0 36.6 24.4 39.0
191
Chapter 23
Table 23.16: Adenocarcinoma of the Urinary Bladder: Number and Distribution of Cases and Median Survival Time (Months) by AJCC Stage (5th Edition) and Sex, Ages 20+, 12 SEER Areas, 1988-2001 Male Female AJCC Median Median Stage Survival Survival (5th Cases % Cases % Time Time Edition) (Months) (Months) Total Stage 0/I Stage II Stage III Stage IV Unknown 540 100.0 78 77 63 132 190 14.4 14.3 11.7 24.4 35.2 36.1 75.4 57.3 48.4 11.6 43.4 298 100.0 30 34 53 80 101 10.1 11.4 17.8 26.8 33.9 24.9 > 120 56.4 43.2 12.7 18.4
had approximately the same age distribution, the median survival times may be longer for the females since women have longer life expectancy than men. Squamous cell carcinomas and adenocarcinomas were rare. Overall survival rates among males for adenocarcinoma were 3 times higher than for squamous cell carcinoma, while among females it was 2.5 times higher. The survival advantage typically associated with early stage disease was less apparent for squamous cell carcinoma.
REFERENCES
1. American Cancer Society. Cancer facts & figures 2006, The American Cancer Society, Atlanta, (GA), 2006. 2. Miller BA, Kolonel LN, Bernstein L, Young, Jr. JL, Swanson GM, West D, Key CR, Liff JM, Glover CS, Alexander GA, et al. (eds). Racial/Ethnic Patterns of Cancer in the United States 1988-1992, National Cancer Institute. NIH Pub. No. 96-4104. Bethesda, MD, 1996.Lynch CF, Cohen MB. Urinary System. Cancer 1995;75:316-329. 3. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M, Hankey BF, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer. cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006. 4. Mungen NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, Kiemeney LA. Gender differences in stage-adjusted bladder cancer survival. Urology 2000; 55(6):876-880. 5. Underwood W, Dunn RL, Williams C, Lee CT. Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. J Am Coll Surg 2006; 2002 (2):284-290. 6. Prout GR Jr, Wesley MN, Greenberg RS, Chen VW, Brown CC, Miller AW, Weinstein RS, Robboy SJ, Haynes MA, Blacklow RS, Edwards BK. Bladder cancer: Race differences in extent of disease at diagnosis. Cancer 2000; 89(6)1349-1358. 7. Epstein JI, Amin MB, Reuter VR, Mostofi FK, and the Bladder Consensus Conference Committee. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22(12):1435-1448.
192